CDX-110 / GBM / $300mCDX-110 / other indications / $500mCDX-011 / BC / $400mCDX-011 / Melanoma / $400mCDX-1307 / Bladder / $500mCDX-1401 / Multiple tumors / $300mCDX-1135 / Renal disease / $500CDX-014 / Ovarian / $500Rest / CDX-1127, CDX-301 / $500In some years this could be a multibillion company. maybe next year will be a game changer.Start P3/CDX-110, preliminary results CDX-011 and CDX-1307.As they have so many candidates I thin we will see some partnerships soon.Show me another biotech company with several drugs in midstage trials you can get for a market cap of just $140m.Patience will be rewarded. Do not worry about the up and downs.Marc
Marc, approx when might initial data come out for cdx-011 or cdx-1307?
hei, clearvoyant.1.how do you know that?2. how do you know how many of cldx project will get fda accept?3. add many dilutive actions.as a result you will get 2-5 bucks share price in 2 years.dead money here for a long time.
hei, hillbillybetter go back and bash Avanir.Marc